The effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients: Prospective randomized study with volumetric intravascular ultrasonography analysis

Korean Circulation Journal

Volumn 40, Issue 12, 2010, Pages 625-631

  You, Sung Hye ^a   Kim, Beum Suk ^a   Hong, Soon Jun ^a   Ahn, Chul Min ^a   Lim, Do Sun ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Diabetes mellitus; Intravascular ultrasonography; Neointima; Pioglitazone

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICORANDIL; NITRATE; PIOGLITAZONE; RETINOL BINDING PROTEIN 4; SULFONYLUREA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ZOTAROLIMUS;

ADULT; AGED; ARTERY INTIMA; ARTERY OCCLUSION; ARTERY RUPTURE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; DRUG ELUTING STENT; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMPLANTATION; INFLAMMATION; INSULIN RESISTANCE; INTRAVASCULAR ULTRASOUND; MALE; NEOINTIMA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SERUM GROUP PI SYSTEM; SINGLE BLIND PROCEDURE; STENT; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR NECROSIS;

EID: 79551714212     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2010.40.12.625     Document Type: Article

References (21)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31. (Pubitemid 28405191)
2. Hong SJ, Kim MH, Ahn TH, et al. Comparison of the predictors of coronary restenosis after drug-eluting stent implantation in diabetic and nondiabetic patients. Korean Circ J 2007;37:530-7.
3. Lee MG, Jeong MH, Ahn YK, et al. Comparison of clinical outcomes following acute myocardial infarctions in hypertensive patients with or without diabetes. Korean Circ J 2009;39:243-50.
4. Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925-31. (Pubitemid 40814110)
5. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008;24:14-26. (Pubitemid 351175996)
6. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. (Pubitemid 46919772)
7. Forst T, Hohberg C, Fuellert SD, et al. Pharmacological PPARγ stimulation in contrast to beta cell stimulation results in an improvement in adipo nectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res 2005;37:521-7. (Pubitemid 41306404)
8. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111:2525-31.
9. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73. (Pubitemid 351482795)
10. Tamborlane WV, Ahern J. Implications and results of the diabetes control and complications trial. Pediatr Clin North Am 1997;44:285-300.
11. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38. (Pubitemid 43974725)
12. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-56.
13. Wu Z, Xie Y, Morrison RF, Bucher NL, Farmer SR. PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J Clin Invest 1998;101:22-32. (Pubitemid 28058899)
14. Fonseca VA. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Am J Med 2007;120(9 Suppl 2):S18-25.
15. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-8.
16. Chen KW, Boyko EJ, Bergstrom RW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995;18:747-53.
17. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 1997;20:1562-8. (Pubitemid 27415035)
18. Shimizu H, Oh-I S, Tsuchiya T, Ohtani KI, Okada S, Mori M. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-α levels in Type 2 diabetic patients: a randomized study. Diabet Med 2006;23:253-7.
19. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91. (Pubitemid 23036092)
20. Desouza CV, Murthy SN, Diez J, et al. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. J Cardiovasc Pharmacol Ther 2003;8:297-305. (Pubitemid 38045081)
21. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO-active Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89. (Pubitemid 41416583)